125 related articles for article (PubMed ID: 37165578)
21. A transforming Src mutant increases the bioavailability of EGFR ligands via stimulation of the cell-surface metalloproteinase ADAM17.
Maretzky T; Zhou W; Huang XY; Blobel CP
Oncogene; 2011 Feb; 30(5):611-8. PubMed ID: 20871631
[TBL] [Abstract][Full Text] [Related]
22. FGF18-FGFR2 signaling triggers the activation of c-Jun-YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential.
Zhang J; Wong CC; Leung KT; Wu F; Zhou Y; Tong JHM; Chan RCK; Li H; Wang Y; Yan H; Liu L; Wu WKK; Chan MWY; Cheng ASL; Yu J; Wong N; Lo KW; To KF; Kang W
Oncogene; 2020 Oct; 39(43):6647-6663. PubMed ID: 32934314
[TBL] [Abstract][Full Text] [Related]
23. FGF7/FGFR2-JunB signalling counteracts the effect of progesterone in luminal breast cancer.
Mieczkowski K; Kitowska K; Braun M; Galikowska-Bogut B; Gorska-Arcisz M; Piasecka D; Stawiski K; Zaczek AJ; Nejc D; Kordek R; Romanska HM; Sadej R
Mol Oncol; 2022 Aug; 16(15):2823-2842. PubMed ID: 35726195
[TBL] [Abstract][Full Text] [Related]
24. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
Borad MJ; Champion MD; Egan JB; Liang WS; Fonseca R; Bryce AH; McCullough AE; Barrett MT; Hunt K; Patel MD; Young SW; Collins JM; Silva AC; Condjella RM; Block M; McWilliams RR; Lazaridis KN; Klee EW; Bible KC; Harris P; Oliver GR; Bhavsar JD; Nair AA; Middha S; Asmann Y; Kocher JP; Schahl K; Kipp BR; Barr Fritcher EG; Baker A; Aldrich J; Kurdoglu A; Izatt T; Christoforides A; Cherni I; Nasser S; Reiman R; Phillips L; McDonald J; Adkins J; Mastrian SD; Placek P; Watanabe AT; Lobello J; Han H; Von Hoff D; Craig DW; Stewart AK; Carpten JD
PLoS Genet; 2014 Feb; 10(2):e1004135. PubMed ID: 24550739
[TBL] [Abstract][Full Text] [Related]
25. FGFR2 alterations in endometrial carcinoma.
Gatius S; Velasco A; Azueta A; Santacana M; Pallares J; Valls J; Dolcet X; Prat J; Matias-Guiu X
Mod Pathol; 2011 Nov; 24(11):1500-10. PubMed ID: 21725289
[TBL] [Abstract][Full Text] [Related]
26. FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
Cristinziano G; Porru M; Lamberti D; Buglioni S; Rollo F; Amoreo CA; Manni I; Giannarelli D; Cristofoletti C; Russo G; Borad MJ; Grazi GL; Diodoro MG; Giordano S; Sacconi A; Forcato M; Anastasi S; Leonetti C; Segatto O
J Hepatol; 2021 Aug; 75(2):351-362. PubMed ID: 33741397
[TBL] [Abstract][Full Text] [Related]
27. Rapid Identification of FGFR2 Gene Mutations in Taiwanese Patients With Endometrial Cancer Using High-resolution Melting Analysis.
Lin YC; Er TK; Yeh KT; Hung CH; Chang JG
Appl Immunohistochem Mol Morphol; 2015 Aug; 23(7):532-7. PubMed ID: 25517871
[TBL] [Abstract][Full Text] [Related]
28. PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2
Packer LM; Geng X; Bonazzi VF; Ju RJ; Mahon CE; Cummings MC; Stephenson SA; Pollock PM
Mol Cancer Ther; 2017 Apr; 16(4):637-648. PubMed ID: 28119489
[TBL] [Abstract][Full Text] [Related]
29. Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.
Dai B; Yan S; Lara-Guerra H; Kawashima H; Sakai R; Jayachandran G; Majidi M; Mehran R; Wang J; Bekele BN; Baladandayuthapani V; Yoo SY; Wang Y; Ying J; Meng F; Ji L; Roth JA
PLoS One; 2015; 10(6):e0123967. PubMed ID: 26053020
[TBL] [Abstract][Full Text] [Related]
30. Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancer.
Packer LM; Stehbens SJ; Bonazzi VF; Gunter JH; Ju RJ; Ward M; Gartside MG; Byron SA; Pollock PM
Mol Oncol; 2019 Apr; 13(4):738-756. PubMed ID: 30537101
[TBL] [Abstract][Full Text] [Related]
31. FGFR2 as a molecular target in endometrial cancer.
Byron SA; Pollock PM
Future Oncol; 2009 Feb; 5(1):27-32. PubMed ID: 19243295
[TBL] [Abstract][Full Text] [Related]
32. Blocking NOTCH pathway can enhance the effect of EGFR inhibitor through targeting CD133+ endometrial cancer cells.
Shang C; Lang B; Meng LR
Cancer Biol Ther; 2018 Feb; 19(2):113-119. PubMed ID: 27791463
[TBL] [Abstract][Full Text] [Related]
33. P2Y2 nucleotide receptors mediate metalloprotease-dependent phosphorylation of epidermal growth factor receptor and ErbB3 in human salivary gland cells.
Ratchford AM; Baker OJ; Camden JM; Rikka S; Petris MJ; Seye CI; Erb L; Weisman GA
J Biol Chem; 2010 Mar; 285(10):7545-55. PubMed ID: 20064929
[TBL] [Abstract][Full Text] [Related]
34. Emodin regulating excision repair cross-complementation group 1 through fibroblast growth factor receptor 2 signaling.
Chen G; Qiu H; Ke SD; Hu SM; Yu SY; Zou SQ
World J Gastroenterol; 2013 Apr; 19(16):2481-91. PubMed ID: 23674849
[TBL] [Abstract][Full Text] [Related]
35. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.
Nagatsuma AK; Aizawa M; Kuwata T; Doi T; Ohtsu A; Fujii H; Ochiai A
Gastric Cancer; 2015 Apr; 18(2):227-38. PubMed ID: 24626858
[TBL] [Abstract][Full Text] [Related]
36. Dysregulation of the ADAM17/Notch signalling pathways in endometriosis: from oxidative stress to fibrosis.
González-Foruria I; Santulli P; Chouzenoux S; Carmona F; Chapron C; Batteux F
Mol Hum Reprod; 2017 Jul; 23(7):488-499. PubMed ID: 28486700
[TBL] [Abstract][Full Text] [Related]
37. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.
Kunii K; Davis L; Gorenstein J; Hatch H; Yashiro M; Di Bacco A; Elbi C; Lutterbach B
Cancer Res; 2008 Apr; 68(7):2340-8. PubMed ID: 18381441
[TBL] [Abstract][Full Text] [Related]
38. ADAM17 participates in the protective effect of paeoniflorin on mouse brain microvascular endothelial cells.
Wang H; Ma S; Li J; Zhao M; Huo X; Sun J; Sun L; Hu J; Liu Q
J Cell Physiol; 2018 Dec; 233(12):9320-9329. PubMed ID: 29215702
[TBL] [Abstract][Full Text] [Related]
39. FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).
Katoh Y; Katoh M
Int J Mol Med; 2009 Mar; 23(3):307-11. PubMed ID: 19212647
[TBL] [Abstract][Full Text] [Related]
40. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.
Byron SA; Gartside M; Powell MA; Wellens CL; Gao F; Mutch DG; Goodfellow PJ; Pollock PM
PLoS One; 2012; 7(2):e30801. PubMed ID: 22383975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
